Avelas’ Intraoperative Imaging Device simultaneously images two far red and near infra-red wavelengths to realize the advantages of ratiometric fluorescent readout of pegloprastide for real-time cancer detection.

Pegloprastide’s ratiometric readout attenuates common artifacts of fluorescent imaging, including differences in drug concentration and distance of the camera from the tissue area of interest. Pegloprastide is the only fluorescence-based clinical cancer detection product that utilizes ratiometric imaging to provide more accurate and actionable information during a procedure.

Avelas’ device has a wide field of view (~10 cm) and provides a rapid assessment of tissue (~100 ms). Avelas’ imaging system may be used on various sample types, including excised specimen, shave margins, and in vivo in a patient’s cavity. Display overlay software provides an objective prediction of cancer in real-time to surgeons, giving them the necessary information to make clinical decisions to improve outcomes for patients.